reports
- GlobalData Healthcare Department
MEI Pharma Inc (MEIP) - Financial Analysis Review
Summary MEI Pharma Inc (MEIP) - Financial Analysis Review Summary MEI Pharma Inc (MEI), formerly Marshall Edwards Inc is an oncology company that offers clinical development of novel therapies for cancer. The company’s drug candidates comprise pracinostat, an oral HDAC inhibitor which is intended for the treatment of acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis. Its also develops ME-344, a mitochondrial inhibitor for the treatment of HER2-negative Breast indication; an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.